Current Rheumatology Reports

, Volume 5, Issue 1, pp 33–40 | Cite as

Advanced glycation endproducts and osteoarthritis

  • Deborah M. Saudek
  • Jonathan Kay

Abstract

Non-enzymatic glycation of proteins, such as collagen, results in the formation of advanced glycation endproducts (AGE). Advanced glycation endproducts result in pathologic stiffening of cartilage and extracellular matrix and accumulate with age. Pentosidine, an AGE, is present in serum, synovial fluid, and articular cartilage from patients with osteoarthritis (OA). However, AGE levels are not always increased, and may be decreased locally, in association with osteoarthritic pathology. The finding of pentosidine in articular cartilage of individuals with OA may not be specific for that disease, independent of chronologic age. Advanced glycation endproduct modification of normal articular cartilage increases its stiffness, increases chondrocyte-mediated proteoglycan degradation, reduces its susceptibility to matrix metalloproteinase-mediated degradation, and decreases proteoglycan synthesis by chondrocytes. These observations parallel findings in osteoarthritic cartilage, which suggests that AGE modification could contribute to the pathogenesis of OA. However, a causative link between AGEs and OA has not yet been established.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Felson DT, Zhang Y, Hannan MT, et al.: The incidence and natural history of knee osteoarthritis in the elderly. The Framingham Osteoarthritis Study. Arthritis Rheum 1995, 38:1500–1555.PubMedCrossRefGoogle Scholar
  2. 2.
    Davis MA, Ettinger WH, Neuhaus JM: Obesity and osteoarthritis of the knee: evidence from the National Health and Nutrition Examination Survey (NHANES I). Semin Arthritis Rheum 1990, 20(suppl):34–41.PubMedCrossRefGoogle Scholar
  3. 3.
    Takahashi M, Kushida K, Ohishi T, et al.: Quantitative analysis of crosslinks pyridinoline and pentosidine in articular cartilage of patients with bone and joint disorders. Arthritis Rheum 1994, 37:724–728.PubMedCrossRefGoogle Scholar
  4. 4.
    Verzijl N, DeGroot J, Ben ZC, et al.: Crosslinking by advanced glycation end products increases the stiffness of the collagen network in human articular cartilage: a possible mechanism through which age is a risk factor for osteoarthritis. Arthritis Rheum 2002, 46:114–123. In vitro incubation of articular cartilage with ribose or threose increases its AGE content and stiffness.PubMedCrossRefGoogle Scholar
  5. 5.
    Monnier VM, Kohn RR, Cerami A: Accelerated age-related browning of human collagen in diabetes mellitus. Proc Natl Acad Sci U S A 1984, 81:583–587.PubMedCrossRefGoogle Scholar
  6. 6.
    Vlassara H, Bucala R, Striker L: Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 1994, 70:138–151.PubMedGoogle Scholar
  7. 7.
    Hunt JV, Wolff SP: Oxidative glycation and free radical production: a causal mechanism of diabetic complications. Free Radic Res Commun 1991, 12:115–123.PubMedGoogle Scholar
  8. 8.
    Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813–820.PubMedCrossRefGoogle Scholar
  9. 9.
    Hamada Y, Araki N, Koh N, et al.: Rapid formation of advanced glycation end products by intermediate metabolites of glycolytic pathway and polyol pathway. Biochem Biophys Res Commun 2003, 228:539–543.CrossRefGoogle Scholar
  10. 10.
    Bucala R, Vlassara H, Cerami A: Advanced glycosylation endproducts. In Post-translational modification of proteins, vol 2. Edited by Harding J, James M, Crabbe C. Boca Raton: CRC Press; 1992:53–79.Google Scholar
  11. 11.
    Baynes JW: The role of AGEs in aging: causation or correlation. Exp Gerontol 2001, 36:1527–1537.PubMedCrossRefGoogle Scholar
  12. 12.
    Higgins PJ, Bunn HF: Kinetic analysis of the nonenzymatic glycosylation of hemoglobin. J Biol Chem 1981, 256:5204–5208.PubMedGoogle Scholar
  13. 13.
    Dyer DG, Dunn JA, Thorpe SR, et al.: Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 1993, 91:2463–2469.PubMedGoogle Scholar
  14. 14.
    Makita Z, Bucala R, Rayfield EJ, et al.: Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 1994, 343:1519–1522.PubMedCrossRefGoogle Scholar
  15. 15.
    Verzijl N, DeGroot J, Thorpe SR, et al.: Effect of collagen turnover on the accumulation of advanced glycation end products. J Biol Chem 2000, 275:39027–39031.PubMedCrossRefGoogle Scholar
  16. 16.
    Monnier VM, Glomb M, Elgawish A, Sell DR: The mechanism of collagen cross-linking in diabetes: a puzzle nearing resolution. Diabetes 2003, 45(suppl):S67-S72.Google Scholar
  17. 17.
    Hadley JC, Meek KM, Malik NS: Glycation changes the charge distribution of type I collagen fibrils. Glycoconj J 1998, 15:835–840.PubMedCrossRefGoogle Scholar
  18. 18.
    Hou FF, Chertow GM, Kay J, et al.: Interaction between beta 2- microglobulin and advanced glycation end products in the development of dialysis related-amyloidosis. Kidney Int 1997, 51:1514–1519.PubMedCrossRefGoogle Scholar
  19. 19.
    Miyata T, Ishiguro N, Yasuda Y, et al.: Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers. Biochem Biophys Res Commun 1998, 244:45–49.PubMedCrossRefGoogle Scholar
  20. 20.
    Chen JR, Takahashi M, Suzuki M, et al.: Pentosidine in synovial fluid in osteoarthritis and rheumatoid arthritis: relationship with disease activity in rheumatoid arthritis. J Rheumatol 1998, 25:2440–2444.PubMedGoogle Scholar
  21. 21.
    Chen JR, Takahashi M, Suzuki M, et al.: Comparison of the concentrations of pentosidine in the synovial fluid, serum and urine of patients with rheumatoid arthritis and osteoarthritis. Rheumatology 1999, 38:1275–1278. Pentosidine is present in serum, urine, and synovial fluid but levels are lower in patients with OA than in those with RA.PubMedCrossRefGoogle Scholar
  22. 22.
    Bank RA, Bayliss MT, Lafeber FP, et al.: Ageing and zonal variation in post-translational modification of collagen in normal human articular cartilage: the age-related increase in nonenzymatic glycation affects biomechanical properties of cartilage. Biochem J 1998, 330:345–351.PubMedGoogle Scholar
  23. 23.
    Takahashi M, Suzuki M, Kushida K, et al.: The effect of aging and osteoarthritis on the mature and senescent cross-links of collagen in human meniscus. Arthroscopy 1998, 14:366–372.PubMedCrossRefGoogle Scholar
  24. 24.
    Bank RA, Verzijl N, Lafeber FP, Tekoppele JM: Putative role of lysyl hydroxylation and pyridinoline cross-linking during adolescence in the occurrence of osteoarthritis at old age. Osteoarthritis Cartilage 2002, 10:127–134.PubMedCrossRefGoogle Scholar
  25. 25.
    Gibson GJ, Verner JJ, Nelson FR, Lin DL: Degradation of the cartilage collagen matrix associated with changes in chondrocytes in osteoarthrosis: assessment by loss of background fluorescence and immunodetection of matrix components. J Orthop Res 2001, 19:33–42. This study uses background fluorescence to measure total AGE content in articular cartilage from individuals with OA and demonstrates decreased fluorescence around chondrocytes.PubMedCrossRefGoogle Scholar
  26. 26.
    DeGroot J, Verzijl N, Bank RA, et al.: Age-related decrease in proteoglycan synthesis of human articular chondrocytes: the role of nonenzymatic glycation. Arthritis Rheum 1999, 42:1003–1009. Pentosidine levels in articular cartilage increase linearly with chronologic aging. Proteoglycan synthesis decreases in articular cartilage after in vitro incubation with ribose and correlates with an increase in pentosidine content.PubMedCrossRefGoogle Scholar
  27. 27.
    Pokharna HK, Monnier V, Boja B, Moskowitz RW: Lysyl oxidase and Maillard reaction-mediated crosslinks in aging and osteoarthritic rabbit cartilage. J Orthop Res 1995, 13:13–21.PubMedCrossRefGoogle Scholar
  28. 28.
    Dunn JA, McCance DR, Thorpe SR, et al.: Age-dependent accumulation of N epsilon-(carboxymethyl)lysine and N epsilon- (carboxymethyl)hydroxylysine in human skin collagen. Biochemistry 1991, 30:1205–1210.PubMedCrossRefGoogle Scholar
  29. 29.
    Grushko G, Schneiderman R, Maroudas A: Some biochemical and biophysical parameters for the study of the pathogenesis of osteoarthritis: a comparison between the processes of aging and degeneration in human hip cartilage. Connect Tissue Res 1989, 19:149–176.PubMedGoogle Scholar
  30. 30.
    DeGroot J, Verzijl N, Jacobs KM, et al.: Accumulation of advanced glycation endproducts reduces chondrocyte-mediated extracellular matrix turnover in human articular cartilage. Osteoarthritis Cartilage 2001, 9:720–726. Both proteoglycan synthesis and chondrocyte-mediated cartilage degradation decrease after human articular cartilage has been AGE-modified by incubation with reducing sugars.PubMedCrossRefGoogle Scholar
  31. 31.
    DeGroot J, Verzijl N, Wenting-Van Wijk MJ, et al.: Age-related decrease in susceptibility of human articular cartilage to matrix metalloproteinase-mediated degradation: the role of advanced glycation end products. Arthritis Rheum 2001, 44:2562–2571. Glycosaminoglycan release from normal human articular cartilage, after in vitro incubation with synovial fluid obtained from patients with RA or OA, is decreased proportional to the pentosidine content of the cartilage and is independent of the cartilage donor’s chronologic age.PubMedCrossRefGoogle Scholar
  32. 32.
    Lander HM, Tauras JM, Ogiste JS, et al.: Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 1997, 272:17810–17814.PubMedCrossRefGoogle Scholar
  33. 33.
    Yan SD, Schmidt AM, Anderson GM, et al.: Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994, 269:9889–9897.PubMedGoogle Scholar
  34. 34.
    Schmidt AM, Hori O, Cao R, et al.: RAGE: a novel cellular receptor for advanced glycation end products. Diabetes 2003 45(suppl):S77-S80.Google Scholar
  35. 35.
    Vlassara H, Li YM, Imani F, et al.: Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med 1995, 1:634–646.PubMedGoogle Scholar
  36. 36.
    Kay J, Hou F-F, Quigley C, et al.: The advanced glycosylation endproduct binding protein AGE-R3 (galectin-3) is present in synovial tissues from patients with b2m amyloidosis [abstract]. Arthritis Rheum 1999, 42(suppl):S159.Google Scholar
  37. 37.
    Oshima S, Kuchen S, Seemayer CA, et al.: Galectin-3 and galectin- 3 binding protein are up-regulated in rheumatoid arthritis and contribute to joint destruction [abstract]. Arthritis Rheum 2002, 46(suppl):S502.Google Scholar
  38. 38.
    Reboul PY, Boileau C, Guévremont M, et al.: Galectin-3 is expressed on the surface of adult chondrocytes. What’s for? [abstract]. Arthritis Rheum 2002, 46(suppl):S86.Google Scholar
  39. 39.
    Pricci F, Leto G, Amadio L, et al.: Role of galectin-3 as a receptor for advanced glycosylation end products. Kidney Int Suppl 2000, 77:S31-S39.PubMedCrossRefGoogle Scholar
  40. 40.
    Pugliese G, Pricci F, Leto G, et al.: The diabetic milieu modulates the advanced glycation end product-receptor complex in the mesangium by inducing or upregulating galectin-3 expression. Diabetes 2000, 49:1249–1257.PubMedCrossRefGoogle Scholar
  41. 41.
    Stitt AW, He C, Vlassara H: Characterization of the advanced glycation end-product receptor complex in human vascular endothelial cells. Biochem Biophys Res Commun 1999, 256:549–556.PubMedCrossRefGoogle Scholar
  42. 42.
    Hou FF, Jiang JP, Guo JQ, et al.: Receptor for advanced glycation end products on human synovial fibroblasts: role in the pathogenesis of dialysis-related amyloidosis. J Am Soc Nephrol 2002, 13:1296–1306.PubMedCrossRefGoogle Scholar
  43. 43.
    Schmidt AM, Yan SD, Brett J, et al.: Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J Clin Invest 1993, 91:2155–2168.PubMedGoogle Scholar
  44. 44.
    Yan SD, Yan SF, Chen X, et al.: Non-enzymatically glycated tau in Alzheimer’s disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide. Nat Med 1995, 1:693–699.PubMedCrossRefGoogle Scholar
  45. 45.
    Vlassara H, Brownlee M, Manogue KR, et al.: Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 1988, 240:1546–1548.PubMedCrossRefGoogle Scholar
  46. 46.
    Morohoshi M, Fujisawa K, Uchimura I, Numano F: The effect of glucose and advanced glycosylation end products on IL-6 production by human monocytes. Ann N Y Acad Sci 1995, 748:562–570.PubMedCrossRefGoogle Scholar
  47. 47.
    el Khoury J, Thomas CA, Loike JD, et al.: Macrophages adhere to glucose-modified basement membrane collagen IV via their scavenger receptors. J Biol Chem 1994, 269:10197–10200.PubMedGoogle Scholar
  48. 48.
    Ohgami N, Nagai R, Ikemoto M, et al.: Cd36, a member of the class b scavenger receptor family, as a receptor for advanced glycation end products. J Biol Chem 2001, 276:3195–3202.PubMedCrossRefGoogle Scholar
  49. 49.
    Raskin P, Cattran D, Williams M, et al.: Pimagedine (PG) reduces progression of retinopathy and lowers lipid levels in patients with type I diabetes mellitus (DM) [abstract]. J Am Soc Nephrol 1999, 10:179A.Google Scholar
  50. 50.
    Appel G, Bolton K, Freedman B, et al.: Pimagedine (PG) lowers total urinary protein (TUP) and slows progression of overt diabetic nephropathy in patients with type I diabetes mellitus (DM) [abstract]. J Am Soc Nephrol 1999, 10:153A.Google Scholar
  51. 51.
    Shirazi I, Yaron I, Wollman Y, et al.: Downregulation of interleukin 1beta production in human osteoarthritic synovial tissue and cartilage cultures by aminoguanidine. Ann Rheum Dis 2001, 60:391–394.PubMedCrossRefGoogle Scholar
  52. 52.
    Brownlee M, Vlassara H, Kooney A, et al.: Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986, 232:1629–1632.PubMedCrossRefGoogle Scholar
  53. 53.
    McAlindon T, Felson DT: Nutrition: risk factors for osteoarthritis. Ann Rheum Dis 1997, 56:397–400.PubMedCrossRefGoogle Scholar
  54. 54.
    Miyata T, Hori O, Zhang J, et al.: The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloidosis. J Clin Invest 2003, 98:1088–1094.CrossRefGoogle Scholar
  55. 55.
    Vasan S, Zhang X, Kapurniotu A, et al.: An agent cleaving glucose- derived protein crosslinks in vitro and in vivo. Nature 2003, 382:275–278.CrossRefGoogle Scholar
  56. 56.
    Wolffenbuttel BH, Boulanger CM, Crijns FR, et al.: Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci U S A 1998, 95:4630–4634.PubMedCrossRefGoogle Scholar
  57. 57.
    Asif M, Egan J, Vasan S, et al.: An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness. Proc Natl Acad Sci U S A 2000, 97:2809–2813.PubMedCrossRefGoogle Scholar
  58. 58.
    Vaitkevicius PV, Lane M, Spurgeon H, et al.: A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys. Proc Natl Acad Sci U S A 2001, 98:1171–1175.PubMedCrossRefGoogle Scholar
  59. 59.
    Kass DA, Shapiro EP, Kawaguchi M, et al.: Improved arterial compliance by a novel advanced glycation endproduct crosslink breaker. Circulation 2001, 104:1464–1470.PubMedGoogle Scholar
  60. 60.
    Vlassara H, Palace MR: Diabetes and advanced glycation endproducts. J Intern Med 2002, 251:87–101.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2003

Authors and Affiliations

  • Deborah M. Saudek
  • Jonathan Kay
    • 1
  1. 1.Rheumatology UnitMassachusetts General HospitalBostonUSA

Personalised recommendations